Navigation Links
Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/5/2009

RICHMOND, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 2:00 pm (PT) on Monday, January 12, 2009 at the J.P. Morgan Healthcare Conference in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and amyotrophic lateral sclerosis (ALS). Other therapeutic development programs are focused on HIV/AIDS, cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic areas including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
2. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
3. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
4. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
5. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
6. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
7. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
8. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
9. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
10. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
11. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Morris ... open house for regional manufacturers at its Maple Grove, Minnesota technical center, May ... Group, Chiron and Trumpf. Almost 20 leading suppliers of tooling, accessories, software ...
(Date:4/27/2016)... April 27, 2016 NanoStruck ... (OTCPink: NSKQB) ( Frankfurt : 8NSK) ... Pressemitteilung vom 13. August 2015 die Genehmigung von ... um zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu ... bringen. Davon wurden 157.900.000 Einheiten mit dem ersten ...
(Date:4/27/2016)... ... April 27, 2016 , ... A ... (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems. ... novel treatments in small animal subjects. Simultaneous PET/MRI imaging offers a solution to ...
(Date:4/26/2016)... ... 27, 2016 , ... Cameron Cushman has joined ... in the firm’s Intellectual Property practice group. , Clients turn to Cushman for ... has an electrical engineering and computer engineering background, and experience in the medical ...
Breaking Biology Technology:
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
Breaking Biology News(10 mins):